Cytokinetics chief legal officer sells $794,877 in shares
Cytokinetics Inc. (NASDAQ: CYTK) Chief Legal & Administrative Officer Jeffrey Hessekiel sold 15,106 shares of the company's common stock on November 17, 2026, for a total of $794,877. The shares were sold at $52.62 per share, and the sale was intended to cover tax withholding obligations related to the vesting and settlement of restricted stock units.
This transaction was mandated by the company and not a discretionary decision made by Hessekiel. After the sale, Hessekiel owned 92,837 shares of Cytokinetics common stock. The stock price was trading near its 52-week low of $51 and had decreased by 8.6% over the previous week. Analysts view the stock as undervalued, with a Fair Value of $61.76, and six analysts have recently raised their earnings estimates.
Cytokinetics reported strong quarterly results in Q3 2026, surpassing expectations with MYQORZO treatment sales and an adjusted loss of $1.37 per share, while revenue reached $47.6 million, exceeding the forecasted $40.61 million.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.